<- Go Home
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Market Cap
$6.5M
Volume
1.7M
Cash and Equivalents
$3.3M
EBITDA
-$7.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$4.17
52 Week Low
$0.77
Dividend
N/A
Price / Book Value
1.01
Price / Earnings
-0.22
Price / Tangible Book Value
1.01
Enterprise Value
$3.2M
Enterprise Value / EBITDA
-0.40
Operating Income
-$7.3M
Return on Equity
320.96%
Return on Assets
-104.18
Cash and Short Term Investments
$3.3M
Debt
N/A
Equity
$4.3M
Revenue
N/A
Unlevered FCF
-$3.0M
Sector
Pharmaceuticals
Category
N/A